Anaptysbio (ANAB) Assets Average (2017 - 2026)
Anaptysbio's (ANAB) quarterly Assets Average came in at $347.0 million in Q1 2026, down 23.38% YoY from $452.9 million in Q1 2025, and down 3.26% on a QoQ basis from $358.7 million in Q4 2025.
Anaptysbio (ANAB) Assets Average (2017 - 2026) Analysis & Trends
Anaptysbio (ANAB) has 10 years of Assets Average data on file, last reported at $347.0 million in Q1 2026.
- Quarterly Assets Average fell 23.38% year-over-year to $347.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $347.0 million (down 23.38% YoY) and the FY2025 annual result came in at $424.1 million, down 9.4% from the prior year.
- Assets Average slipped to $347.0 million in Q1 2026, from $358.7 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $634.1 million in Q1 2022 to a low of $344.2 million in Q3 2025.
- A 5-year average of $484.6 million and a median of $469.9 million in 2023 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2022 — Assets Average jumped 56.0% — and 2025, when it declined 26.58%.
- Tracing ANAB's Assets Average over 5 years: stood at $614.4 million in 2022, then slipped by 23.53% to $469.9 million in 2023, then climbed by 3.99% to $488.6 million in 2024, then decreased by 26.58% to $358.7 million in 2025, then slipped by 3.26% to $347.0 million in 2026.
- The last three Assets Average figures came in at $347.0 million (Q1 2026), $358.7 million (Q4 2025), and $344.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Anaptysbio | 1.70 Bn | 1.41 Bn | - | 347.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 347.04 Mn |
| Dec 31, 2025 | 358.75 Mn |
| Sep 30, 2025 | 344.17 Mn |
| Jun 30, 2025 | 378.65 Mn |
| Mar 31, 2025 | 452.94 Mn |
| Dec 31, 2024 | 488.63 Mn |
| Sep 30, 2024 | 460.40 Mn |
| Jun 30, 2024 | 416.61 Mn |
| Mar 31, 2024 | 429.11 Mn |
| Dec 31, 2023 | 469.86 Mn |
| Sep 30, 2023 | 502.21 Mn |
| Jun 30, 2023 | 534.45 Mn |
| Mar 31, 2023 | 581.09 Mn |
| Dec 31, 2022 | 614.44 Mn |
| Sep 30, 2022 | 611.18 Mn |
| Jun 30, 2022 | 614.51 Mn |
| Mar 31, 2022 | 634.12 Mn |
| Dec 31, 2021 | 533.70 Mn |
| Sep 30, 2021 | 425.45 Mn |
| Jun 30, 2021 | 411.49 Mn |